MY194920A - Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof - Google Patents

Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof

Info

Publication number
MY194920A
MY194920A MYPI2016701265A MYPI2016701265A MY194920A MY 194920 A MY194920 A MY 194920A MY PI2016701265 A MYPI2016701265 A MY PI2016701265A MY PI2016701265 A MYPI2016701265 A MY PI2016701265A MY 194920 A MY194920 A MY 194920A
Authority
MY
Malaysia
Prior art keywords
polysaccharide
protein
protein conjugates
present
enhanced immunogenicity
Prior art date
Application number
MYPI2016701265A
Inventor
Davinder Gill
Manoj Kumar Chhikara
Rakesh Rana
Juned Dalal
Deepti Singh
Vibhu Kanchan
Original Assignee
Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Wellcome Trust Hilleman Laboratories Pvt Ltd filed Critical Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Priority claimed from IN3047DE2013 external-priority patent/IN2013DE03047A/en
Publication of MY194920A publication Critical patent/MY194920A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Sustainable Development (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to polysaccharide ? protein conjugates with enhanced immunogenicity displaying significantly high antibody titres. The carrier protein is obtained from group of gram positive bacteria, polysaccharide fragment is obtained from group of gram negative bacteria, preferably from Haemophilus influenzae serotype b (Hib), Neisseria meningitidis serogroup A and C (MenA and MenC). The present invention also relates to a rapid and high yielding process of preparing the polysaccharide?protein conjugates in which derivatized carrier protein reacts with cleaved and depolymerized polysaccharide fragments of optimum length to obtain polysaccharide ? protein conjugate employing reductive amination chemistry. The present invention further relates to a chemical process of polysaccharide fragmentation to optimum length for use in conjugation.
MYPI2016701265A 2013-10-11 2014-10-10 Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof MY194920A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2363DE2014 2014-08-20
PCT/IB2014/065201 WO2015052684A2 (en) 2013-10-11 2014-10-10 Polysaccharide-protein conjugates with enhanced immunogenicity and rapid high yielding process thereof
IN3047DE2013 IN2013DE03047A (en) 2013-10-11 2014-10-10

Publications (1)

Publication Number Publication Date
MY194920A true MY194920A (en) 2022-12-23

Family

ID=52144766

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016701265A MY194920A (en) 2013-10-11 2014-10-10 Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof

Country Status (4)

Country Link
CN (1) CN105636608A (en)
MY (1) MY194920A (en)
WO (1) WO2015052684A2 (en)
ZA (1) ZA201602375B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105770890A (en) * 2016-03-08 2016-07-20 苏文全 Specific protein composition and application method thereof
CN106084037B (en) * 2016-06-08 2020-01-07 中国人民解放军第二军医大学 A kind of Bacillus anthracis capsule surface trisaccharide conjugate and its preparation method and application
BR112019003992A2 (en) 2016-09-02 2019-05-28 Sanofi Pasteur Inc neisseria meningitidis vaccine
US11027005B2 (en) * 2016-10-20 2021-06-08 Km Biologics Co., Ltd. Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
CN114965784B (en) * 2022-06-01 2023-10-27 艾美探索者生命科学研发有限公司 Method for measuring polysaccharide activation degree

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008348A1 (en) * 1993-09-22 1995-03-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process

Also Published As

Publication number Publication date
WO2015052684A3 (en) 2015-07-23
ZA201602375B (en) 2017-07-26
CN105636608A (en) 2016-06-01
WO2015052684A2 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
MX2020002558A (en) Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein.
MY194920A (en) Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof
EA201391788A1 (en) VACCINE CONTAINING CONJUGATES OF CAPSULAR POLYSACCHARIDES STREPTOCOCCUS PNEUMONIAE
MX2021014710A (en) An immunogenic serotype 35b pneumococcal polysaccharide-protein conjugate and conjugation process for making the same.
MX2014009250A (en) Immunogenic composition.
CY1112677T1 (en) COUNCIL PULMONIC COGNACULAR COGNAC GULF Vaccine
WO2015012904A3 (en) Antibody-sn-38 immunoconjugates with a cl2a linker
MX371454B (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof.
PH12018501517A1 (en) Neisseria meningitidis compositions and methods thereof
MX2013013111A (en) Multiple antigen presenting immunogenic composition, and methods and uses thereof.
EP2601969A3 (en) Norovirus vaccine formulations
BRPI0413323B8 (en) method for preparing a meningococcal tetanus toxoid conjugate vaccine in commercial volumes
MX351345B (en) Conjugation process of bacterial polysaccharides to carrier proteins.
CL2011002369A1 (en) An immunogenic composition comprising: a conjugated pneumococcal capsular saccharide, including depolymerized saccharide of serotype 18c; and meningococcal factor h (fhbp) binding protein antigen, but not including meningococcal membrane vesicles. and method of preparation of the composition.
AR080122A1 (en) COMPOSITION OF CONJUGATED VACCINE OF POLISACARIDO-PROTEIN NEUMOCOCICA 15-VALENTE
CL2007003781A1 (en) Method for the preparation of an immunogenic conjugate comprising the polysaccharide of streptococcus pneumoniae serotype 1 covalently linked to a carrier protein; and process for preparing a multivalent polysaccharide-protein immunogenic composition.
MX2016009469A (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof.
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
MX2014005244A (en) Antigen binding protein and its use as addressing product for the treatment of cancer.
JO2840B1 (en) Vaccine
WO2011156774A3 (en) Multivalent glycopeptide constructs and uses thereof
MY199399A (en) Novel polysaccharide-protein conjugates and process to obtain thereof
EP4512477A3 (en) Improved lamp constructs
TN2017000126A1 (en) An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof
IN2013DE03047A (en)